Non enteric-coated, chewable aspirin (162 mg to 325 mg) I should be given to all patients with NSTE- ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 mg/d to 325 mg/d) should be continued indefinite- (Level of Evidence: A) 2. In patients with NSTE-ACS who are unable to take aspirin because of hypersensitivity or major gastro- intestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be ad- (Level of Evidence: B) inhibitor (either clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTE-ACS without con- traindications who are treated with either an early in- vasive or ischemia-guided strategy. Options include: Clopidogrel: 300-mg or 600-mg loading dose, then (Level of Evidence: B) Ticagrelor : 180-mg loading dose, then 90 mg (Level of Evidence: B) Class IIa 1. It is reasonable to use ticagrelor in preference to clop- idogrel for P2Y12 treatment in patients with NSTE- ACS who undergo an early invasive or ischemia- (Level of Evidence: B) Class IIb 1. In patients with NSTE-ACS treated with an early inva- sive strategy and dual antiplatelet therapy (DAPT) with intermediate/high-risk features (eg, positive troponin), a GP IIb/IIIa inhibitor may be considered as part of ini- tial antiplatelet therapy. Preferred options are eptifiba- tide or tirofiban.43,94,295 (Level of Evidence: B) Despite the large number of new antiplatelet and antithrombotic agents, aspirin, which targets COX and subsequent throm- inhibition, is the mainstay of antiplatelet therapy. 